Advertisement
Canada markets open in 5 hours 16 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7331
    +0.0008 (+0.11%)
     
  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     
  • Bitcoin CAD

    87,815.75
    +509.92 (+0.58%)
     
  • CMC Crypto 200

    1,387.57
    -8.97 (-0.64%)
     
  • GOLD FUTURES

    2,360.20
    +17.70 (+0.76%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,760.00
    +192.50 (+1.10%)
     
  • VOLATILITY

    15.50
    +0.13 (+0.85%)
     
  • FTSE

    8,122.03
    +43.17 (+0.53%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Pyng Medical Completes Convertible Note Amendments

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 3, 2014) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) is pleased to announce that it has completed amendments to the terms of certain previously issued secured convertible notes dated August 10, 2009 (the "2009 Notes") in the aggregate principal amount of $530,000.

The Company amended the maturity date of the 2009 Notes from August 8, 2014 to August 8, 2015 and revised the price at which the principal of the 2009 Notes is convertible into common shares of the Company from $0.20 per common share to $0.06 per common share. In consideration of the foregoing amendments, each holder of an amended 2009 Note was issued one non-transferable common share purchase warrant (each, a "Warrant") for every $0.06 of the principal amount of their notes. The Warrants will have an exercise price of $0.065 per Warrant and a term of one year.

The Warrants and 2009 Notes will be subject to a hold period of four months from the date of issuance in accordance with the rules and policies of the TSX-V and applicable Canadian securities laws. The creation of any "control persons" (as defined in the policies of the TSX-V) as a result of the foregoing transactions will be subject to TSX-V approval.

About Pyng Medical Corp.

Pyng Medical Corp. engineers and markets award-winning trauma and resuscitation products for front-line critical care personnel world-wide. Pyng's product portfolio includes innovative sternal intraosseous (sternal IO) pelvic stabilization and tourniquet devices specifically designed and customized for both the military and civilian markets. With growing markets in North America, Europe and Asia, Pyng develops user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

ADVERTISEMENT

More information about Pyng is available on SEDAR at www.sedar.com under the Company's profile and on its website: www.pyng.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbour Statement; Forward-Looking Statements: This release contains forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.